Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-AHFIRM: Larsucosterol in Alcohol-associated Hepatitis
NCT07428538Phase 3Recruiting
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alcoholic hepatitis (AH) comparing Larsucosterol 30 mg with Placebo (2 arms). Primary endpoint: Transplant Free Survival at Day 90. Started Jan 2026; status: recruiting.
02
Drugs
larsucosterol
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT07428538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07428538.